# Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

> **NCT01591902** · PHASE4 · TERMINATED · sponsor: **Theratechnologies** · enrollment: 129 (actual)

## Conditions studied

- Diabetic Retinopathy
- HIV

## Interventions

- **DRUG:** Tesamorelin
- **DRUG:** Placebo-Control

## Key facts

- **NCT ID:** NCT01591902
- **Lead sponsor:** Theratechnologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-06
- **Primary completion:** 2018-05
- **Final completion:** 2018-08
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2018-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01591902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01591902, "Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01591902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*